Koers Prana Biotechnology Limited Nasdaq
Aandelen
US7397272045
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 2,58 mln. 2,42 mln. | Omzet 2025 * | 3,77 mln. 3,53 mln. | Marktkapitalisatie | 13,93 mln. 13,03 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -12 mln. -11,23 mln. | Nettowinst (verlies) 2025 * | -11 mln. -10,29 mln. | EV/omzet 2024 * | 4,19 x |
Nettoliquiditeiten 2024 * | 3,11 mln. 2,91 mln. | Nettoliquiditeiten 2025 * | 6,62 mln. 6,2 mln. | EV/omzet 2025 * | 1,94 x |
K/w-verhouding 2024 * |
-
| K/w-verhouding 2025 * |
-
| Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 86,93% |
Recentste transcriptie over Prana Biotechnology Limited
Managers | Titel | Leeftijd | Van |
---|---|---|---|
David Stamler
CEO | Chief Executive Officer | 63 | 01-05-17 |
Geoffrey Kempler
FOU | Founder | 69 | 11-11-97 |
Phillip Hains
DFI | Director of Finance/CFO | 64 | 01-05-14 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Geoffrey Kempler
FOU | Founder | 69 | 11-11-97 |
Peter Marks
BRD | Director/Board Member | 68 | 29-07-05 |
Lawrence Gozlan
BRD | Director/Board Member | 45 | 08-08-11 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+38,36% | 52,73 mld. | |
+38,93% | 39 mld. | |
-8,63% | 38,52 mld. | |
+25,46% | 30,38 mld. | |
-11,17% | 26,39 mld. | |
+11,44% | 26,08 mld. | |
+45,09% | 14,15 mld. | |
+32,93% | 12,6 mld. | |
-5,30% | 11,51 mld. |